J M Sanchez-Tapias

Summary

Affiliation: University of Barcelona
Country: Spain

Publications

  1. ncbi Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virolo
    J M Sanchez-Tapias
    Hospital Clinic i Provincial, Barcelona
    Methods Find Exp Clin Pharmacol 24:579-84. 2002
  2. ncbi Nosocomial transmission of hepatitis C virus
    J M Sanchez-Tapias
    Liver Unit, IMD Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    J Hepatol 31:107-12. 1999
  3. ncbi Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients
    Jose M Sanchez-Tapias
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, IDIBAPS, Spain
    Gastroenterology 123:1848-56. 2002
  4. ncbi Hepatitis C: who should you treat and how?
    Jose M Sanchez Tapias
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Blood Purif 20:124-36. 2002
  5. ncbi The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
    J C Saiz
    Hospital Clinic, Department of Medicine, Facultad de Medicina, Universidad de Barcelona, Spain
    J Infect Dis 177:839-47. 1998
  6. ncbi Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation
    M Coto-Llerena
    Liver Unit, CIBERehd, IDIBAPS, Barcelona, Spain
    Am J Transplant 11:1051-7. 2011
  7. ncbi High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis
    M Gimenez-Barcons
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 34:158-67. 2001
  8. ncbi Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center
    X Forns
    Department of Medicine, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Universitat de Barcelona, Catalonia, Spain
    J Hepatol 35:265-71. 2001
  9. ncbi Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature
    M Ramos-Casals
    Department of Autoimmune Diseases, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, School of Medicine, University of Barcelona, Barcelona, Spain
    J Viral Hepat 12:648-54. 2005
  10. ncbi Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
    S M Martinez
    Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 33:138-48. 2011

Collaborators

Detail Information

Publications16

  1. ncbi Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virolo
    J M Sanchez-Tapias
    Hospital Clinic i Provincial, Barcelona
    Methods Find Exp Clin Pharmacol 24:579-84. 2002
    ..Secondary efficacy variables are the rate of sustained biochemical response, the rate of response in function of HCV genotype, viral load and treatment duration. Safety data will also be recorded and analyzed...
  2. ncbi Nosocomial transmission of hepatitis C virus
    J M Sanchez-Tapias
    Liver Unit, IMD Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    J Hepatol 31:107-12. 1999
    ..Thus, although prospective studies have not been performed, nosocomial transmission of HCV unrelated to haemodialysis appears to be an infrequent and preventable event...
  3. ncbi Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients
    Jose M Sanchez-Tapias
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, IDIBAPS, Spain
    Gastroenterology 123:1848-56. 2002
    ..The aim of this study was to investigate if the variable outcome of chronic hepatitis B may be related to hepatitis B virus (HBV) genotype...
  4. ncbi Hepatitis C: who should you treat and how?
    Jose M Sanchez Tapias
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Blood Purif 20:124-36. 2002
    ....
  5. ncbi The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
    J C Saiz
    Hospital Clinic, Department of Medicine, Facultad de Medicina, Universidad de Barcelona, Spain
    J Infect Dis 177:839-47. 1998
    ..In conclusion, low virus load and mutant NS5A-ISDR phenotype are closely associated with long-term response to interferon in HCV genotype 1b- but probably not in 3a-infected patients...
  6. ncbi Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation
    M Coto-Llerena
    Liver Unit, CIBERehd, IDIBAPS, Barcelona, Spain
    Am J Transplant 11:1051-7. 2011
    ..Interestingly, donor genotype also seems to influence the response pattern, especially in recipients who have a favorable IL28B genotype...
  7. ncbi High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis
    M Gimenez-Barcons
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 34:158-67. 2001
    ..Therefore, a mutated HCV-PKR-bd phenotype is very common in cirrhotic patients with hepatocellular carcinoma...
  8. ncbi Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center
    X Forns
    Department of Medicine, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Universitat de Barcelona, Catalonia, Spain
    J Hepatol 35:265-71. 2001
    ..The natural history of chronic hepatitis C (HCV) is not completely understood. This study was aimed to evaluate the long-term outcome of the disease over a prolonged period of time and to identify factors associated with progression...
  9. ncbi Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature
    M Ramos-Casals
    Department of Autoimmune Diseases, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, School of Medicine, University of Barcelona, Barcelona, Spain
    J Viral Hepat 12:648-54. 2005
    ..Two-thirds of these patients presented an associated SAD, mainly Sjögren's syndrome or systemic sclerosis, together with a high frequency of multiple autoantibodies and an increased prevalence of cirrhosis and neoplasia...
  10. ncbi Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
    S M Martinez
    Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 33:138-48. 2011
    ..Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C...
  11. ncbi Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection
    M Ramos-Casals
    Department of Autoimmune Diseases, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    J Viral Hepat 14:736-42. 2007
    ..Associated HIV infection significantly attenuated the clinical and immunological expression of cryoglobulinaemia, except in coinfected patients with high viral loads for the two viruses...
  12. ncbi Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    Jose M Sanchez-Tapias
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gastroenterology 131:451-60. 2006
    ..This study investigated whether treatment for 72 weeks increases the rate of SVR in patients with detectable hepatitis C virus (HCV)-RNA levels at week 4 of treatment...
  13. ncbi Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation
    A Sanchez-Fueyo
    Liver Unit, Institut Clinic de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    J Med Virol 65:266-75. 2001
    ..These findings suggest that the degree of amino acid diversification in the HVR1 of HCV, which probably reflects the strength of immune pressure on HCV, is inversely related to the histological severity of HCV infection recurrence...
  14. ncbi Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania
    C Menendez
    Unidad de Epidemiologia y Bioestadistica, Institut d Investigacions Biomedicas August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    J Med Virol 58:215-20. 1999
    ..The results of this study show for the first time in Africa that mother-to-infant transmission does not play a significant role in the acquisition of HCV infection...
  15. ncbi Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Hepatology 49:22-31. 2009
    ..47). Conclusion: In patients with HIV, HCV therapy with PEG 2b or PEG 2a plus RBV had no significant differences in efficacy and safety...
  16. ncbi Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
    Francesc Puig-Basagoiti
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina IMD, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Gen Virol 86:1067-75. 2005
    ..These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy...